TACTILE SYSTEMS TECHNOLOGY INC
Close on Oct 19, 2026
- Market cap
- $524.13M
- P/E (TTM)
- 21.0
- Dividend yield
- –
About Tactile Systems Technology
Surgical & Medical Instruments & Apparatus, SIC 3841
Tactile Systems Technology, doing business as Tactile Medical, develops medical devices for people managing chronic conditions at home. Its portfolio centers on vascular disease, oncology complications, and chronic respiratory disorders. Core offerings include pneumatic compression platforms such as Flexitouch Plus, Entre Plus, and Nimbl, which treat lymphedema, phlebolymphedema, and chronic venous insufficiency. The company also provides AffloVest, a portable oscillating vest that clears airway secretions for patients with bronchiectasis or neuromuscular conditions, alongside Kylee, a digital therapy tracking application. The firm primarily serves patients with chronic conditions, working directly with healthcare providers and distributing respiratory products through durable medical equipment suppliers.
The enterprise operates throughout the United States as an accredited home medical equipment provider. Its commercial reach includes nationwide field teams of account managers and specialists who train patients and engage prescribing clinicians. Reincorporated as a Delaware corporation after originally forming in Minnesota, the company does not state its headquarters location in the provided text.
Summary of the business section of Tactile Systems Technology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TACTILE SYSTEMS TECHNOLOGY INC
- Founded
- 1995
- Headquarters
- Minneapolis, MN
- Address
- 1331 Tyler Street Ne Ste 200 55413
- Phone
- (866) 435-3948
- Employees
- 1,086, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Minnesota
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- TCMD
- Exchange
- Nasdaq
- IPO date
- Jul 28, 2016
- Shares outstanding
- 23M, Aug 6, 2026
- Public float
- $223.03M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1027838
- CUSIP
- 87357P100
- ISIN
- US87357P1003
- LEI
- 54930069VDTITHOTKJ98
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sheri Louise Dodd | Chief Executive Officer, Director | 232,907 |
| Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | 130,188 |
| Kristie Burns | Sr. VP Mktg & Clinical Affairs | 82,581 |
| Raymond Huggenberger | Director | 62,841 |
| Valerie L. Asbury | Director | 55,343 |
| David Brent Shafer | Director | 55,343 |
| Boyd Vindell Washington | Director | 41,768 |
| Laura G. King | Director | 25,569 |
| Andrea Pearson | Director | 7,373 |
| Carmen B. Volkart | Director | 44,219 |
| William W. Burke | Director | 55,041 |
| Daniel L. Reuvers | Director | 214,604 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Sheri L.Dodd | $3.47M | $6.33M | $1.53M | $65 | $78 |
| FY2024 Reuvers | $2.63M | $797.44K | $1.14M | $38 | $78 |
| FY2024 Sheri L.Dodd | $2.48M | $2.82M | $1.14M | $38 | $78 |
| FY2023 Reuvers | $2.87M | $3.21M | $755.92K | $32 | $74 |
| FY2022 Reuvers | $3.22M | $1.85M | $1.17M | $26 | $79 |
| FY2021 Reuvers | $2.08M | $459.48K | $941.78K | $42 | $103 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,086 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 17, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 28, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 10, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |